Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Author： Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.142, Iss.1, 2013-11, pp. : 69-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

By Abe Hajime  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

By Andersen Kenneth Geving   Jensen Maj-Britt   Kehlet Henrik   Gärtner Rune   Eckhoff Lise   Kroman Niels  

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1036-1044

Informa Healthcare

Access to resources Recommend Favorite

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

By Ramaswamy Bhuvaneswari   Povoski Steven   Rhoades Chris   Allen Joan   Hauger Marsha   Young Donn   Burak William   Farrar William   Yee Lisa   Kendra Kari   Somasundaram Sivagurunathan   Orlowski Robert   Shapiro Charles  

Breast Cancer Research and Treatment, Vol. 93, Iss. 1, 2005-09 ,pp. : 67-74

Springer Publishing Company

Access to resources Recommend Favorite

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

By Hatschek T.   Carlsson L.   Einbeigi Z.   Lidbrink E.   Linderholm B.   Lindh B.   Loman N.   Malmberg M.   Rotstein S.   Söderberg M.   Sundquist M.   Walz T.   Hellström M.   Svensson H.   Åström G.   Brandberg Y.   Carstensen J.   Fernö M.   Bergh J.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 939-947

Springer Publishing Company

Access to resources Recommend Favorite

Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

By Lindman Henrik   Åström Gunnar   Ahlgren Johan   Villman Kenneth   Blomqvist Carl   Nygren Peter   Bergh Jonas  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 165-171

Informa Healthcare

Access to resources Recommend Favorite